ProPhase Labs Inc (PRPH) - Cash Flow Conversion Efficiency

Latest as of September 2025: -3.137x

Based on the latest financial reports, ProPhase Labs Inc (PRPH) has a cash flow conversion efficiency ratio of -3.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.52 Million) by net assets ($6.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

ProPhase Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)

This chart illustrates how ProPhase Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PRPH total liabilities for a breakdown of total debt and financial obligations.

ProPhase Labs Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ProPhase Labs Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Twin Vee Powercats Co
NASDAQ:VEEE
-0.166x
Multistack International Ltd
AU:MSI
-0.730x
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
-0.145x
Kavango Resources PLC
LSE:KAV
-0.160x
Chelverton UK Dividend Trust PLC
LSE:SDV
0.024x
Hennessy Capital Investment Corp. VII Rights
NASDAQ:HVIIR
N/A
Water Ways Technologies Inc
V:WWT
-0.008x
PROPHECY DEFI INC.
F:V8M
N/A

Annual Cash Flow Conversion Efficiency for ProPhase Labs Inc (1996–2024)

The table below shows the annual cash flow conversion efficiency of ProPhase Labs Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see PRPH market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $7.35 Million $-17.54 Million -2.385x -937.94%
2023-12-31 $49.38 Million $-11.35 Million -0.230x -151.21%
2022-12-31 $63.63 Million $28.55 Million 0.449x +293.16%
2021-12-31 $58.63 Million $-13.62 Million -0.232x +5.40%
2020-12-31 $10.56 Million $-2.59 Million -0.246x -227.91%
2019-12-31 $11.23 Million $-841.00K -0.075x +41.68%
2018-12-31 $16.50 Million $-2.12 Million -0.128x -49.70%
2017-12-31 $33.09 Million $-2.84 Million -0.086x -8.34%
2016-12-31 $5.96 Million $-472.00K -0.079x +80.01%
2015-12-31 $8.83 Million $-3.50 Million -0.396x -31.98%
2014-12-31 $10.72 Million $-3.22 Million -0.300x -432.47%
2013-12-31 $12.60 Million $1.14 Million 0.090x +118.04%
2012-12-31 $11.45 Million $-5.73 Million -0.500x -166.43%
2011-12-31 $11.23 Million $-2.11 Million -0.188x +28.78%
2010-12-31 $13.46 Million $-3.55 Million -0.264x -933.02%
2009-12-31 $14.06 Million $445.00K 0.032x +118.40%
2008-12-31 $17.77 Million $-3.06 Million -0.172x -205.56%
2007-12-31 $23.30 Million $-1.31 Million -0.056x -250.57%
2006-12-31 $25.59 Million $956.94K 0.037x -77.76%
2005-12-31 $25.37 Million $4.27 Million 0.168x -20.79%
2004-12-31 $21.96 Million $4.66 Million 0.212x +556.59%
2003-12-31 $20.79 Million $-966.23K -0.046x -257.52%
2002-12-31 $18.42 Million $543.64K 0.030x +156.01%
2001-12-31 $21.20 Million $-1.12 Million -0.053x +40.24%
2000-12-31 $21.21 Million $-1.87 Million -0.088x -277.69%
1999-12-31 $26.20 Million $1.30 Million 0.050x -75.14%
1998-12-31 $44.60 Million $8.90 Million 0.200x -7.54%
1997-12-31 $41.70 Million $9.00 Million 0.216x +123.54%
1996-12-31 $1.20 Million $-1.10 Million -0.917x --

About ProPhase Labs Inc

NASDAQ:PRPH USA Diagnostics & Research
Market Cap
$639.50K
Market Cap Rank
#30629 Global
#5934 in USA
Share Price
$0.14
Change (1 day)
+3.29%
52-Week Range
$0.07 - $0.97
All Time High
$14.70
About

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more